Reported 1 day ago
Summit Therapeutics Inc. (NASDAQ:SMMT) is generating interest in the biotech sector, yet analysts hold conflicting views. While Leerink Partners and Barclays have set Sell ratings without precise targets, Truist Financial maintains a Buy rating, and Citi has a positive outlook with a $35 target. With SMMT’s innovative focus on treatments for infectious and cancerous diseases, investors may see it as a worthwhile option despite the caution advised due to potentially higher-risk alternatives.
Source: YAHOO